J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence

 
• By Jessica Merrill

The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.

Janssen vaccine
J&J recorded $100m in COVID-19 vaccine sales in the first quarter • Source: Alamy (Markus Mainka / Alamy Stock Phot/Alamy Stock Photo)

More from COVID-19

More from Scrip